In-Vitro Activity of Dimercaptosuccinic Acid in Combination with Carbapenems Against Carbapenem-Resistant Pseudomonas aeruginosa
Microbial Drug Resistance · 2025
DOI: 10.1089/mdr.2024.0104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Drug Resistance, 2025. Verfasst von Maxime Bouvier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, Microbial Sensitivity Tests, beta-Lactamases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Carbapenenemase producers, particularly the metallo-β-lactamase (MBL) types in Pseudomonas aeruginosa , have emerged as an urgent threat in health care settings. MBLs require zinc at their catalytic site and can be inhibited by dimercaptosuccinic acid (DMSA), a metal chelator known for the treatment of lead and mercury intoxication. Isogenic strains of wild-type and OprD-deleted P. aeruginosa PA14, were constructed, producing the MBLs VIM-2, NDM-1, SPM-1, IMP-1, and AIM-1, or the non-MBL carbapenemases, GES-5 and KPC-2. In addition, 59 previously characterized clinical isolates of P. aeruginosa producing different ß-lactamases (including carbapenemases), and with known outer-membrane porin OprD status, were utilized. Minimal inhibitory concentrations values of imipenem and meropenem, and DMSA combinations were determined, and time-kill assays were performed with PA14 expressing VIM-2. Results indicated a significant additive effect of DMSA (most effective at 3 mM) and carbapenems in recombinant and clinical strains of P. aeruginosa expressing MBLs, in particular against VIM producers, which are the most prevalent carbapenemases in P. aeruginosa . This effect was best evidenced with meropenem and in strains without OprD modification. DMSA shows promising efficacy, particularly in combination therapy with meropenem, for treating infections caused by MBL-producing P. aeruginosa .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.
- Institute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland.
Zitieren
APA
Bouvier, M., Freire, S., Findlay, J., & Nordmann, P. (2025). In-Vitro Activity of Dimercaptosuccinic Acid in Combination with Carbapenems Against Carbapenem-Resistant Pseudomonas aeruginosa. Microbial Drug Resistance. https://doi.org/10.1089/mdr.2024.0104
Vancouver
Bouvier M, Freire S, Findlay J, Nordmann P. In-Vitro Activity of Dimercaptosuccinic Acid in Combination with Carbapenems Against Carbapenem-Resistant Pseudomonas aeruginosa. Microbial Drug Resistance. 2025. doi:10.1089/mdr.2024.0104
BibTeX
@article{Bouvier2025,
author = {Bouvier, Maxime and Freire, Samanta and Findlay, Jacqueline and Nordmann, Patrice},
title = {In-Vitro Activity of Dimercaptosuccinic Acid in Combination with Carbapenems Against Carbapenem-Resistant Pseudomonas aeruginosa},
journal = {Microbial Drug Resistance},
year = {2025},
doi = {10.1089/mdr.2024.0104}
}
EUVIMED